[go: up one dir, main page]

WO2016016774A8 - Crystalline forms of canagliflozin - Google Patents

Crystalline forms of canagliflozin Download PDF

Info

Publication number
WO2016016774A8
WO2016016774A8 PCT/IB2015/055559 IB2015055559W WO2016016774A8 WO 2016016774 A8 WO2016016774 A8 WO 2016016774A8 IB 2015055559 W IB2015055559 W IB 2015055559W WO 2016016774 A8 WO2016016774 A8 WO 2016016774A8
Authority
WO
WIPO (PCT)
Prior art keywords
canagliflozin
crystalline forms
crystalline form
crystalline
hyrate
Prior art date
Application number
PCT/IB2015/055559
Other languages
French (fr)
Other versions
WO2016016774A1 (en
Inventor
Ramkinkar SANTRA
Devendra Prakash NAGDA
Ram Thaimattam
Satish Kumar Aryan
Tarun Kumar SINGH
Mohan Prasad
Somenath Ganguly
Deepika WADHWA
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Publication of WO2016016774A1 publication Critical patent/WO2016016774A1/en
Publication of WO2016016774A8 publication Critical patent/WO2016016774A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to crystalline forms of canagliflozin, processes for their preparation, and their use for the treatment of type 2 diabetes mellitus. A crystalline Form R3 pf canagliflozin hyrate. The crystalline Form R-3 canagliflozin hydrate, characterized by an X-ray powder diffraction peaks having d-spacing values at about 9.2,4.1,4.5, and 7.2 Å.
PCT/IB2015/055559 2014-07-31 2015-07-22 Crystalline forms of canagliflozin WO2016016774A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2156/DEL/2014 2014-07-31
IN2156DE2014 2014-07-31

Publications (2)

Publication Number Publication Date
WO2016016774A1 WO2016016774A1 (en) 2016-02-04
WO2016016774A8 true WO2016016774A8 (en) 2016-03-24

Family

ID=55216825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/055559 WO2016016774A1 (en) 2014-07-31 2015-07-22 Crystalline forms of canagliflozin

Country Status (1)

Country Link
WO (1) WO2016016774A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016536321A (en) * 2013-11-11 2016-11-24 クリスタル ファーマテック カンパニー、リミテッドＣｒｙｓｔａｌ Ｐｈａｒｍａｔｅｃｈ Ｃｏ．， Ｌｔｄ． Canagliflozin B-form, C-form and D-form
EP2990029A1 (en) * 2014-08-29 2016-03-02 Sandoz Ag Pharmaceutical compositions comprising Canagliflozin
JP2018087140A (en) * 2015-02-27 2018-06-07 田辺三菱製薬株式会社 NOVEL CRYSTAL OF 1-(β-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
CN108017626A (en) * 2016-11-04 2018-05-11 上海奥博生物医药技术有限公司 A kind of canagliflozin semihydrate novel crystal forms
CN111487266B (en) * 2020-04-30 2023-10-13 江苏德源药业股份有限公司 Quantitative determination method for monohydrate crystal form in canagliflozin hemihydrate medicinal crystal form

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30730A1 (en) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp CRYSTAL FORM OF HEMIHYDRATE 1- (B (BETA) -D-GLUCOPYRANOSIL) -4-METHYL-3- [5- (4-FLUOROPHENYL) -2-TIENYLMETHYL] BENZENE
US10323056B2 (en) * 2013-05-08 2019-06-18 Lek Pharmaceuticals D.D. Crystalline hydrates of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
JP2016536321A (en) * 2013-11-11 2016-11-24 クリスタル ファーマテック カンパニー、リミテッドＣｒｙｓｔａｌ Ｐｈａｒｍａｔｅｃｈ Ｃｏ．， Ｌｔｄ． Canagliflozin B-form, C-form and D-form
CN103980262B (en) * 2014-04-01 2016-06-22 天津大学 The B crystal form of canagliflozin and crystallization preparation method thereof
CN103936725B (en) * 2014-04-01 2016-07-27 天津大学 The C crystal form of canagliflozin and crystallization preparation method thereof
CN104130246A (en) * 2014-05-28 2014-11-05 华润赛科药业有限责任公司 New crystal form of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene and preparation method thereof

Also Published As

Publication number Publication date
WO2016016774A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
WO2016073693A3 (en) Aadc polynucleotides for the treatment of parkinson's disease
EP3552611A4 (en) Pharmaceutical composition for preventing or treating cancer, comprising tetraarsenic hexoxide crystalline polymorph
WO2016011306A3 (en) Terminal modifications of polynucleotides
WO2016011222A3 (en) Circular polynucleotides
JO3472B1 (en) Dihydrobenzofuran compounds useful in the treatment of diabetes and obesity
WO2016016774A8 (en) Crystalline forms of canagliflozin
PH12015502410B1 (en) Biheteroaryl compounds and uses thereof
WO2016071435A3 (en) Synthesis of copanlisib and its dihydrochloride salt
JP2013521273A5 (en)
WO2015008218A3 (en) Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant
WO2016046260A8 (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators
EP3426260A4 (en) C-glycoside compounds useful for treating disease
WO2015017378A3 (en) Novel copper-cysteamine and methods of use
WO2016080796A3 (en) Pharmaceutical composition, containing sesquiterpene compound, for preventing or treating stat3-mediated diseases, and use thereof
WO2016189443A3 (en) Solid forms of nucleoside phosphoramidate
WO2016088081A8 (en) Processes for the preparation of ertugliflozin
WO2015001541A3 (en) Pharmaceutical film composition
WO2015052568A3 (en) Solid forms of curcumin and derivatives thereof
WO2017214423A3 (en) Derivatives of thailanstatin a, methods of treatment and methods of synthesis thereof
WO2016020408A3 (en) Compounds for preventing ototoxicity
WO2015149656A8 (en) 2,2'-tandem dithiazole compound, preparation method therefor, and use thereof
WO2014195977A3 (en) Novel polymorphs of vismodegib
WO2013121439A3 (en) Garenoxacin mesylate, process for preparation thereof, and crystalline form thereof.
WO2014199244A3 (en) Crystalline imatinib mesylate process
WO2014128728A3 (en) Solid forms of cabazitaxel and processes for preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15826698

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15826698

Country of ref document: EP

Kind code of ref document: A1